Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Market Cap	607M 0 531M 489M 453M 859M 57.9B 874M 5.86B 2.3B 28.43B 2.28B 2.23B 98.49B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	607M 0 531M 489M 453M 859M 57.9B 874M 5.86B 2.3B 28.43B 2.28B 2.23B 98.49B	EV / Sales 2026 *	8.9x	EV / Sales 2027 *	7.14x
Free-Float	90.48%	Yield 2026 *	-	Yield 2027 *	-

06-29	Brainsway Ltd. Presents Positive Data From Largest Real-World Study Of Deep TMS In Patients With Comorbid PTSD And Major Depressive Disorder	CI
06-09	BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	CI
05-18	Hopemark Health, Ltd announced that it expects to receive funding from BrainsWay Ltd.	CI
05-18	Brainsway announces minority-stake investment in Hopemark Health	RE
05-18	BrainsWay Takes Minority Stake in Hopemark Health	MT
05-13	BrainsWay Ltd., Q1 2026 Earnings Call, May 13, 2026
05-13	BrainsWay Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Brainsway Ltd. Reiterates Earnings Guidance for the Year 2026	CI
03-26	Brainsway Provides $6 Million Milestone-Based Convertible Loan to Neurolief	MT
03-19	Brainsway Pays $1 Million Milestone Payment to Axis Management	MT
03-19	Axis Management Company, Inc. announced that it has received $3.3 million in funding from BrainsWay Ltd.	CI
03-11	BrainsWay Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-11	BrainsWay Ltd., Q4 2025 Earnings Call, Mar 11, 2026

11-13	BrainsWay Ltd. Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21	CI
14/05/25	Oppenheimer Adjusts Brainsway Price Target to $15 From $13, Maintains Outperform Rating	MT
09/05/24	Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating	MT
09/05/24	HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating	MT
16/11/23	Oppenheimer Adjusts Price Target on Brainsway to $6 From $5.50, Maintains Outperform Rating	MT

06-29	BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder	AQ
06-22	BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives	AQ
06-09	BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	AQ
05-18	BrainsWay Announces Minority-Stake Investment in Hopemark Health	AQ
05-14	BrainsWay : Q4 2025	PU

Manager	Title	Age	Since
Hadar Levy CEO	Chief Executive Officer	54	13/02/2023
Yiftach Roth CTO	Chief Tech/Sci/R&D Officer	56	01/05/2006
Ido Marom DFI	Director of Finance/CFO	50	23/05/2023

Brainsway Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

BRIN

IL0011007189

Advanced Medical Equipment & Technology

Valuation: Brainsway Ltd

Latest news : Brainsway Ltd

Last Transcript: Brainsway Ltd

Analysts' recommendations: Brainsway Ltd

Press Releases: Brainsway Ltd

Quotes and Performance

Managers and Directors: Brainsway Ltd

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Director	Title	Age	Since
David Zacut CHM	Chairman	74	01/01/2003
Avner Hagai BRD	Director/Board Member	70	01/11/2006
Abraham Zangen BRD	Director/Board Member	56	17/06/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRAINSWAY LTD	+4.71%	-.--%	-	-	607M
THERMO FISHER SCIENTIFIC, INC.	+2.86%	+0.24%	+24.97%	+2.14%	195B
INTUITIVE SURGICAL, INC.	-0.86%	-3.39%	-22.07%	+24.23%	146B
BOSTON SCIENTIFIC CORPORATION	+0.40%	-0.33%	-56.30%	-13.96%	66.87B
EDWARDS LIFESCIENCES CORPORATION	-2.47%	-3.22%	+18.32%	+1.19%	52.59B
SIEMENS HEALTHINEERS AG	+0.07%	-1.74%	-28.19%	-30.88%	43.85B
AGILENT TECHNOLOGIES, INC.	+3.50%	+2.22%	+10.13%	+14.18%	37.73B
WATERS CORPORATION	+2.44%	-0.57%	+8.00%	+42.77%	37.03B
RESMED, INC.	+1.27%	-0.56%	-18.57%	-3.41%	30.07B
GE HEALTHCARE TECHNOLOGIES INC.	+0.03%	-1.32%	-14.32%	-18.74%	29.43B
Average	+1.28%	-1.89%	-8.67%	+1.95%	70.92B
Weighted average by Cap.	+1.11%	-1.81%	-4.21%	+4.99%

	2026 *	2027 *
Net sales	68.15M 0 59.62M 54.98M 50.87M 96.55M 6.5B 98.16M 658M 258M 3.19B 256M 250M 11.06B	84.98M 0 74.34M 68.56M 63.43M 120M 8.11B 122M 821M 322M 3.98B 319M 312M 13.8B
Net income	13.23M 0 11.57M 10.67M 9.88M 18.75M 1.26B 19.06M 128M 50.11M 620M 49.67M 48.6M 2.15B	22.2M 0 19.42M 17.91M 16.57M 31.46M 2.12B 31.98M 215M 84.09M 1.04B 83.35M 81.55M 3.61B
Net Debt	-	-